Zentalis Reports Positive Phase 1b Ovarian Cancer Data for Azenosertib at ASCO

summarizeSummary

Zentalis Pharmaceuticals announced encouraging Phase 1b clinical trial results for azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, showing improved response rates and progression-free survival compared to historical paclitaxel monotherapy.

check_boxKey Events

• Encouraging Phase 1b Results

  Azenosertib combined with paclitaxel achieved a 39.1% Overall Response Rate (ORR) and 7.3-month median Progression-Free Survival (PFS) in platinum-resistant ovarian cancer, outperforming historical paclitaxel monotherapy (approx. 30% ORR, 4-month PFS).

• Optimal Dose Cohort Performance

  The 250 mg intermittent dose cohort demonstrated a 50.0% ORR, including one complete response, and a 9.2-month median Duration of Response (DOR).

• Manageable Safety Profile

  The combination therapy exhibited a manageable safety profile with a low rate of high-grade adverse events across all dose cohorts.

• Broader Applicability Suggested

  Clinical activity was broadly comparable in both Cyclin E1-positive and Cyclin E1-negative patients, suggesting azenosertib's benefit in combination therapy may extend beyond the Cyclin E1 biomarker, which is a key focus for its monotherapy development.

auto_awesomeAnalysis

This filing announces encouraging Phase 1b clinical trial results for Zentalis's lead drug candidate, azenosertib, in combination with paclitaxel for platinum-resistant ovarian cancer. The data shows improved efficacy compared to historical paclitaxel monotherapy, with a higher overall response rate and longer progression-free survival. A manageable safety profile was also observed. This positive data, especially the potential for broader applicability beyond a specific biomarker, strengthens the development path for azenosertib and will be presented at the significant ASCO conference, which could generate further investor interest.